ALK and non-small cell lung carcinoma: Non-small cell lung cancer models that harbour EGFR mutations and ALK rearrangements have demonstrated induction of PD-L1 expression and reduction of PD-L1 when treated with targeted therapies such as EGFR and ALK inhibitors [31, 32].